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Abstract
The KCNH2 and KCNE2 genes encode the cardiac voltage-gated K+ channel KV11.1 and
its auxiliary β subunit KCNE2. KV11.1 is critical for repolarization of the cardiac action poten-
tial. In humans, mutations or drug therapy affecting the KV11.1 channel are associated with
prolongation of the QT intervals on the ECG and increased risk of ventricular tachyarrhyth-
mia and sudden cardiac death—conditions known as congenital or acquired Long QT syn-
drome (LQTS), respectively. In horses, sudden, unexplained deaths are a well-known
problem. We sequenced the cDNA of the KCNH2 and KCNE2 genes using RACE and con-
ventional PCR on mRNA purified from equine myocardial tissue. Equine KV11.1 and
KCNE2 cDNA had a high homology to human genes (93 and 88%, respectively). Equine
and human KV11.1 and KV11.1/KCNE2 were expressed in Xenopus laevis oocytes and
investigated by two-electrode voltage-clamp. Equine KV11.1 currents were larger compared
to human KV11.1, and the voltage dependence of activation was shifted to more negative
values with V1/2 = -14.2±1.1 mV and -17.3±0.7, respectively. The onset of inactivation was
slower for equine KV11.1 compared to the human homolog. These differences in kinetics
may account for the larger amplitude of the equine current. Furthermore, the equine KV11.1
channel was susceptible to pharmacological block with terfenadine. The physiological
importance of KV11.1 was investigated in equine right ventricular wedge preparations. Ter-
fenadine prolonged action potential duration and the effect was most pronounced at slow
pacing. In conclusion, these findings indicate that horses could be disposed to both congen-
ital and acquired LQTS.
PLOS ONE | DOI:10.1371/journal.pone.0138320 September 16, 2015 1 / 19
OPEN ACCESS
Citation: Pedersen PJ, Thomsen KB, Olander ER,
Hauser F, Tejada MdlA, Poulsen KL, et al. (2015)
Molecular Cloning and Functional Expression of the
Equine K+ Channel KV11.1 (Ether à Go-Go-Related/
KCNH2 Gene) and the Regulatory Subunit KCNE2
from Equine Myocardium. PLoS ONE 10(9):
e0138320. doi:10.1371/journal.pone.0138320
Editor: Diego Alvarez de la Rosa, Universidad de La
Laguna, SPAIN
Received: May 12, 2014
Accepted: August 28, 2015
Published: September 16, 2015
Copyright: © 2015 Pedersen et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: Data are available from
the Figshare database: http://dx.doi.org/10.6084/m9.
figshare.1531973, http://dx.doi.org/10.6084/m9.
figshare.1531972, http://dx.doi.org/10.6084/m9.
figshare.1531974.
Funding:Work in the authors’ labs was funded by
grants from Foreningen Kustos af 1881, the Danish
Strategic Research Foundation, the Fraenkel
Foundation, the Medical Research Council, the
Lundbeck Foundation and the National Danish
Foundation for Advanced Technology.
Introduction
In equine medicine, sudden deaths are a well-known problem and often the cause of death can-
not be determined by necropsy [1]. Spontaneous arrhythmias have been shown to occur in
horses [2], but studies coupling specific arrhythmias to sudden cardiac death (SCD) are sparse
[3]. In humans, SCD in athletes has been linked to the Long QT Syndrome (LQTS) [4]. LQTS
is characterized by a delayed repolarization of cardiac action potentials, a prolongation of the
QT interval on the surface ECG and development of ventricular tachyarrhythmia of the tor-
sades de pointes-type, which can progress to SCD. The presence of LQTS in veterinary patients
has been suggested [5], however, reference values of the QT interval are not available for many
companion animals and often the causes of unexpected deaths are not investigated in details
[6].We have recently established the normal QT interval in standard and warmblood horses
[7,8]
Repolarization of the cardiac action potential in larger mammals, including humans and
horses, has been shown to be dependent on the rapid and slow activating delayed rectifier K+
currents, IKr and IKs [6,9,10]. Loss of function mutations in the genes encoding proteins medi-
ating IKr or IKs are common causes of congenital LQTS in humans and pharmaceutical block-
age of IKr is a well described cause of acquired LQTS. IKr is mediated by the pore-forming
protein KV11.1 [11], which has been proposed to interact with the axillary β-subunit KCNE2
in cardiac cells [12]. KV11.1 is encoded by the KCNH2 gene, also known as the ether à go-go
related gene (ERG) due to similarities to the Drosophila ether à go-go (EAG) gene product [13].
The protein KCNE2 is encoded by the KCNE2 gene [12]. Mutations in KCNH2 have been
linked to the long QT syndrome type 2 (LQT2) and mutations in KCNE2 can give rise to LQT6
[12,14,15]. The KV11.1 channel is susceptible to pharmacological block by many compounds,
including antiarrhythmic drugs as well as a variety of non-cardioactive drugs, which has been
linked to acquired LQTS [16]. Acquired LQTS might also be of relevance to equine patients as
horses are often treated with drugs known to prolong cardiac repolarization in other species,
including quinidine, cisapride, erythromycin, and trimethoprim-sulfamethoxazole.
The aim of this study was to obtain a full length cDNA sequence of the equine KCNH2 and
KCNE2 genes and to characterize the electrophysiological properties of equine KV11.1 and
KV11.1/KCNE2 using the human isoform as reference. We found that the overall electrophysi-
ological properties of the cloned equine channels are similar to those of the human isoform.
However, equine KV11.1 currents were larger compared to the human homologue. We also
found that IKr is physiologically important for cardiac repolarization in multicellular prepara-
tions of equine right ventricle. Our results elucidate the function of equine IKr in cardiac repo-
larization and indicate that congenital or acquired LQTS could potentially underlie unexpected
deaths in horses.
Materials and Methods
Ethics Statement
Horses were donated to the Department of Veterinary Clinical and Animal Science, University
of Copenhagen. The horses were euthanized by captive bolt gun and bleeding. No permit for
animal testing was necessary under Danish law (The Animal Experimentation Act 1253 of 8th
of March 2013) to collect the equine tissue used for the experiments. In total, 7 horses were
included, 3 geldings, 1 stallion 3 mares, age 9–10 years and of mixed breed. The prevalent rea-
son for euthanasia was lameness and the horses had no history of any cardiac illnesses.
Xenopus laevis oocytes for heterologous expression were surgically removed from anesthe-
tized frogs (anesthetic compound—0.2% 3-aminobenzoate methanesulfonate). The procedure
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was approved by the Danish animal experimentation board (approval number: 2012-15-2934-
00625).
PCR Primer Design
Predicted equine KCNH2 and KCNE2 gene sequences were obtained by using the Nucleotide
Basic Local Alignment Search Tool (BLAST) [17] to compare the human KCNH2 and KCNE2
sequences (GenBank [18] accession numbers: NM_000218 and NM_172201.1, respectively)
with the genomic sequence data from the EquCab2.0 Equus caballus genome project [19]. The
predicted equine KCNH2 and KCNE2 sequences were used as the query sequence in BLAST
covering all species with an annotated KCNH2 and KCNE2 gene. Following, portions with a
high conservation were used as a basis for manual primer design. Primers were synthesized by
Eurofins MWGOperon (Ebersberg, Germany).
Bioinformatics
For further analysis of conservation, all species with an annotated KCNH2 and KCNE2 gene
were found using the GenBank database or UniProt database [20] and these sequences were
included in multiple sequence alignments generated using MAFFT [21] (Figs 1 and 2).
Cloning of Full-length KV11.1 and KCNE2 cDNA
Equine myocardial tissue was sampled from the left ventricular free wall less than two minutes
after euthanasia. Total RNA was isolated using Trizol reagent (Invitrogen). cDNA was synthe-
sized using the SuperScript III First-Strand Synthesis SuperMix (Invitrogen) or, for Rapid
Amplification of cDNA Ends (RACE), the FirstChoice RLM-RACE kit (Ambion) was used.
Size of PCR products were confirmed by gel electrophoresis and subsequently cloned into the
pCR4-TOPO vector (Invitrogen) using the TOPO TA cloning kit (Invitrogen). Following, the
ligated vectors were transformed into One Shot Top10 and DH5α-T1R competent cells (Invi-
trogen). Plasmid DNA was purified using the GenElute Plasmid Miniprep and kit (Sigma-
Aldrich) and sequenced (Eurofins MWGOperon). Ligation of overlapping coding PCR prod-
ucts was done using T4 DNA ligase after cutting with relevant restriction enzymes (New
England Biolabs). 5’ RACE PCR was unsuccessful for KCNE2. Based on our sequencing results
from conventional PCR, the predicted equine KCNE2 sequenced obtained from EquCab2.0
[19], and sequence alignment with KCNH2 from other species, it was rationalized that the
three amino acids (MPT) initiate the equine KCNE2 protein sequence at the amino terminus.
Based on this assumption the predicted full equine KCNE2 was synthesized by GenScript (Pis-
cataway). To facilitate expression in Xenopus laevis oocytes, the equine KV11.1 and KCNE2
cDNA was subcloned into the pXOOM expression vector [22] and sequenced (Eurofins MWG
Operon). Human KV11.1 (NM_000218) and KCNE2 (NM_172201.1) in pXOOM were kind
gifts from Dr. Thomas Jespersen.
In Vitro Transcription of mRNA
Following linearization of the expression constructs with XbaI (New England Biolabs), mRNA
was produced using the mMessage mMachine kit and purified with MEGAclear (Ambion).
mRNA was stored at -80°C until use.
Isolation of Oocytes and Injection of RNA for Heterologous Expression
Preparation of oocytes from Xenopus laevis was performed as previously described [23]. In
brief, ovarian lobes were excised from the abdominal cavity of anaesthetized frogs. The ovarian
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lobes were digested with collagenase and incubated with hypertonic phosphate buffer to clear
the follicle cell layer from the oocytes. Stage V or VI oocytes were selected and injected with
approximately 50 nl mRNA solution (10 ng for KV11.1 alone and 10/20 ng for KV11.1/
KCNE2) using a micro-injector (Nanoject, Drummond Broomall). Following, the oocytes were
incubated approximately 48 hours at 19°C in kulori medium (in mM): 90 NaCl, 1 KCl, 1
MgCl2, 1 CaCl2, 5 HEPES, pH 7.4
Two-Microelectrode Voltage Clamp of Oocytes
Currents were recorded by two-electrode voltage clamp using an Oocyte Clamp amplifier
(OC-725 B, Warner Instruments) and a PC-interface (Axon Digidata 1440A, Molecular
Devices). Data were sampled at 2 kHz using pClamp (Axon V. 10.2.14, Molecular Devices).
Electrodes were pulled from capillary glass (TW 120–3, WPI) on a programmable micropipette
puller (P-97, Sutter Instrument, Novato, CA, USA). Electrodes were filled with 1 M KCl and
electrode resistance ranged from 0.5 to 1.5 MO. Experiments were performed at room tempera-
ture (19–21°C) in an air-conditioned room with the oocytes in a bath under a continuous flow
of kulori medium. The experiments were repeated in at least three different batches of oocytes
and qualitatively similar results were obtained.
Data were analyzed using Clampfit (Axon 10.4, Molecular Devices) and Prism 5 (GraphPad
Software). The rate of activation of equine vs. human KV11.1 channel and KV11.1/KCNE2 chan-
nel complex was described by fitting a single exponential function I(t) = Aie^(-t/τ) + C to the ini-
tial 500 ms of the activating currents in Fig 3A. Only currents at -20 to 20 mV were included due
to a prominent onset of inactivation at higher voltages. To address the voltage dependence of
activation (Fig 3D), normalized peak tail current amplitude were plotted as a function of test
potentials and a Boltzmann function, I = 1/(1+e^[(V1/2-Vt)/k]) was fitted to the data. V1/2 is the
voltage required for half maximal activation of current, Vt is the test potential, and k is the slope
Fig 1. Alignment of human and equine KV11.1 protein sequences.Genbank accession number: Human
NP_000229, horse ADK92992/ NP_001180587.1. The transmembrane domains S1-S6 are underlined in
red. The α helix at residues 13–23, the PAS domain, the signature sequence at residues 620–629, the Y-652
and the IFG residues in S6, the cyclic nucleotide binding domain (CNBD) at residues 749–872 and the PIP2
binding domain are underlined in blue. Green boxes mark the equine amino acid in position A97S as this
substitution in the PAS domain could be important for channel gating and position 444 as the E444Dmutation
has been published as a cause of long QT syndrome in humans.
doi:10.1371/journal.pone.0138320.g001
Fig 2. Alignment of equine and human KCNE2 protein sequences.Genbank accession number: Human NP_751951, horse AHH41329. The predicted
three amino acids (MPT) initiating the equine KCNE2 protein sequence and the N6 and N29 glycosylation sites and the T71 and S74 phosphorylation sites
are underlined in blue. The transmembrane region is underlined in red.
doi:10.1371/journal.pone.0138320.g002
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factor. The rate of deactivation of equine vs. human KV11.1 channel and KV11.1/KCNE2 channel
complex was obtained by fitting a double exponential function I(t) = ∑Ae^(-t/τ) + C to the
Fig 3. Equine and human KV11.1 expressed in Xenopus laevis oocytes (A) Representative recordings of equine (n>14) and human (n>13) KV11.1
expressed in Xenopus laevis oocytes as well as uninjected controls (n = 15). (B) Steady-state currents (indicated by downward pointing arrow on
the protocol) as a function of voltage. (C) Time-constants (Tau) of the activating currentss. (D) Peak tail currents (indicated by upward pointing
arrow) normalized to maximal amplitude as a function of the voltage at the preceding step.
doi:10.1371/journal.pone.0138320.g003
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deactivating currents in Fig 4A. Voltage dependence of equine and human KV11.1 channel recti-
fication from fast inactivation was determined by comparison of the fully activated I-V relation-
ship for KV11.1 current with the I-V relationship expected for an Ohmic conductor (Fig 5A). A
linear fit of current amplitudes between -110 mV and -90 mV describes the I-V relationship that
would be found in the absence of rectification (Ohmic conduction). The slope determines the
maximum conductance of KV11.1 tail currents, which can be used to calculate voltage depen-
dence of channel rectification, as the rectification factor is given by R = IKv11.1 / (G  n  (Vt—
ERev) where G is the maximal conductance of KV11.1 tail currents, n is the activation variable
at +40 mV (1.0), Vt is the test potential, and Erev, is the reversal potential. The rate of onset of
Fig 4. KV11.1 channel rectification and voltage dependence of inactivation. (A) Representative recordings of equine (n = 10) and human KV11.1 (n = 10)
expressed in Xenopus laevis oocytes. (B) Fully activated current-voltage (I-V) relationship of the equine and human KV11.1 channels. The maximal
conductance (G) of the tail currents was determined as the slope of a linear fit to maximal tail current amplitudes at potential between -120 to -90 mV. (C)
Voltage dependence of rapid inactivation of equine and human Kv11.1. The rectification factor (R) at each potential was calculated using the current
amplitudes plotted in Panel (B) (see Methods for calculation). Data were fitted with a Boltzmann equation.
doi:10.1371/journal.pone.0138320.g004
The Equine Kv11.1 Channel
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inactivation was described by fitting a single exponential function to the data (Fig 6). To describe
pharmacological block of the KV11.1 channel, terfenadine concentrations (0.01, 0.03, 0.1, 0.3, 1.0,
3.0, 10.0 μM) were transformed to log(concentrations) and plotted against current. A non-linear
regression was fitted to the data, to obtain the IC50.
Multicellular Right Ventricular (Wedge) Preparations
The right ventricle was excised and perfused with 4 x 50 mL heparinized (5 IE/L) cardioplegic
solution (in mM: 129 NaCl, 12 KCl, 0.9 NaH2PO4, 20 NaHCO3, 1.8 CaCl2, 0.5 MgSO4, 5.5 glu-
cose, pH 7.4, 4°C) through the coronary artery immediately after isolation and transported in 5
L of heparinized cardioplegic solution. Transmural wedges (4 x 3 x 2 cm) from the right ven-
tricular wall were dissected, canulated and perfused arterially with cardioplegic solution. Leaks
were ligated and the perfusion cannula was sutured to the wedge using 5–0 Mersilene suture
(Ethicon GmbH). Only right ventricles were used as thickness of the left ventricle made it diffi-
cult to obtain viable preparations. The wedge was transferred to a tissue bath and perfused with
oxygenated (95% O2 and 5% CO2) Tyrode’s solution (in mM: 129 NaCl, 4 KCl, 0.9 NaH2PO4,
20 NaHCO3, 1.8 CaCl2, 0.5 MgSO4, 5.5 glucose, pH 7.4) at 36±1°C and at a constant flow rate
using Reglo Digital MS-4/8 tubing pump (Ismatic). The flow was set to 15–20 mL/min depend-
ing on wedge size. The wedge was paced from the endocardial surface using DS3 Constant
Fig 5. Time constants of onset of KV11.1 inactivation. Equine (n = 16) and human (n = 20) KV11.1 expressed in Xenopus laevis oocytes. (A)
Representative recordings. (B) Voltage-clamp protocol. (C) Mono-exponential functions were fit to the inactivating currents as indicated by the arrow on the
protocol and the obtained time constants were plotted as a function of voltage.
doi:10.1371/journal.pone.0138320.g005
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Current Isolated Stimulator (Digitimer Ltd). Basic cycle lengths (BCLs) of 4000, 2000, 1000,
500, 333 and 250 ms were used. Recordings from the midmyocardium were made 30 min after
cannulation (control) and 30 min after application of terfenadine (10 μM) using a floating
microelectrode made from 1B100F-4 glass capillaries with filament (WPI). Microelectrodes
were pulled on a Model P-97 Micropipette Puller (Sutter Instruments) to a resistance of55
MO, when filled with 3 M KCl and connected to a Model 3100 Intracellular Electrometer
(A-M Systems). A transmural ECG was recorded using Ag/AgCl half cells (Warner Instru-
ments) mounted approximately 1 cm from the endo- and epicardial surfaces of the wedge and
connected to an ISO-80 Isolated Bio-Amplifier (WPI). Data was recorded and digitized using
PowerLab 4/20 (ADInstruments) and analyzed using LabChart v8.0.2 (ADInstruments).
Chemicals other than enzymes and kits were obtained from Sigma-Aldrich.
Statistics
All data are expressed as mean±SEM. Normal distribution was tested prior statistical analysis
with KS test (Kolmogorov- Smirnov test with Dallal-Wilkinson Lillie for p-value) and all data
was normal distributed except for Tau values describing KV11.1 deactivation, where the non-
parametric Kruskal Walis and ManWhitney tests were used. Single outliers being more than
three times the SD from the mean were removed from the dataset. Unpaired t- test was used to
compare the equine and human half maximum activation V½ and the slope factors k. All other
Fig 6. Time constants of KV11.1 deactivation. Equine (n = 25) and human (n = 25) KV11.1 expressed in Xenopus laevis oocytes. (A) Representative
recordings. (B) Bi-exponential functions were fitted to the decaying currents (indicated on the protocol by an arrow) and the time constants τfast and τslow were
plotted as a function of voltage. (C) The relative weight of the fast time constant (Taufast).
doi:10.1371/journal.pone.0138320.g006
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data were analyzed using two way ANOVA followed by a Bonferroni test. Statististical level of
significance on figures are shown with : p =0.05, : p =0.01, : p =0.001. All data was
analyzed in Prism5 (GraphPad).
Results
The full sequence of the equine KV11.1 and the partial sequence of the equine KCNE2 cDNA
sequence were submitted to GenBank with the accession numbers HM641824 and KF937396,
respectively. As the KV11.1 channel sequence is 3477 base pairs and highly GC rich it was diffi-
cult to amplify. Therefore, the full sequences was based on a full sequence from only one horse,
which was verified by>50 partial sequences (50–500 base pairs, all with 100% homology) from
five other horses covering different regions, but not the full sequence. Furthermore, our equine
KV11.1 sequence have undergone validation (NP_001180587.1) by Genbank based on compar-
ison to genomic sequence data (AAWR02041039.1) and the transcript is supported by tran-
script alignments and orthologous data. The submitted equine KCNE2 sequence corresponds
to a predicted transcript (XP_001494244) based on computational analysis of a genomic
sequence, using Gnomon (NW_001867397.1). The equine KV11.1 cDNA sequence had 93%
similarity to the human cDNA and the encoded protein sequence had 99% similarity to the
human (Fig 1). The equine KV11.1 cDNA sequence had 88% similarity to the human gene. The
pore, the transmembrane domains S1-S6, and the cyclic nucleotide homology binding domain
(CNBD) of equine KV11.1 were identical to human KV11.1. Most deviations were found in the
N-terminus proximal to the Per-Arnt-Sim (PAS) domain. A single substitution was found
within the PAS domain. The PAS domain is important for channel assembly and for the slow
deactivation gating kinetics of the channel [24] and, interestingly, the p.E444D mutation has
been published as a cause of long QT syndrome in humans [25]. The equine KCNE2 sequence
had 90% similarity to the human KCNE2 (Fig 2). The transmembrane domains were identical
in equine and human KCNE2 and the differences in sequence were found in the distal N- and
C-termini.
The cloned equine KV11.1 was functionally expressed in Xenopus laevis oocytes and represen-
tative equine and human KV11.1 currents recorded by TEVC are shown in Fig 3A. Similarly to
the human isoform, the steady-state current-voltage relationship was bell-shaped (Fig 3B), how-
ever, we repeatedly observed larger currents for equine KV11.1 compared to human (>6 different
batches of Xenopus laevis oocytes, 3 different preparations of mRNA). Endogenous currents
from control oocytes were insignificant (~0.2 μA) and did not affect measurements. As the proxi-
mal domain between the PAS and transmembrane segment 1 has been reported to be crucial for
setting human Kv11.1 activation kinetics, time constants (Tau) of the activating currents were
determined by fitting a mono-exponential equation to initial 500 ms of the current. No differ-
ences in Tau values were found (Fig 3C). It should be noted that since there is an overlap of the
activation and inactivation processes both with regard to time- and voltage-dependence, the
resulting Tau values reflect both these processes. The voltage dependence of activation for
KV11.1 was addressed by plotting normalized currents measured at the -120 mV step as a func-
tion of the preceding test potential and a Boltzmann equation was fitted to the data (Fig 3D).
Test pulses below -60 mV did not result in time-dependent currents. The half maximal activation
(V1/2) was significant different (p = 0.0178) with V1/2 = -17.3±0.7, k = 8.1±0.7, n = 24 for equine
and V1/2 = -14.2±1.1, k = 9.6±1.0, n = 16 for human. The slope factors K were not significantly
different (p = 0.2143).
The degree of channel inactivation was determined from a fully activated KV11.1 current–
voltage relationship (Fig 4). Currents were activated by a +40 mV step and peak tail currents
were plotted as a function of potential (Fig 4B). The maximal conductance of the tail currents (G)
The Equine Kv11.1 Channel
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was determined as the slope of a linear fit to maximal tail current amplitudes at potential between
-120 and -90 mV (Gequine = 159±13 μS and Ghuman = 234±18 μS, n = 10). Voltage dependence of
inactivation was estimated by the rectification factor R (Fig 4C). Reversal potentials were found
to be Erev, equine = -103 mV and Erev, human = -104 mV, n = 10.
The speed of onset of inactivation was determined by activating KV11.1 currents by a +20 mV
step followed by a brief step to -120 mV to release inactivation. A series of steps ranging from
-20 mV to 40 mV resulted in a rapid inactivation of KV11.1 (Fig 5A). To obtain time constants,
mono-exponential functions were fitted to the inactivating currents. The onset of inactivation
was significantly slower for equine KV11.1 compared to human (Fig 5C).
Deactivation was addressed by activating channels by a +20 mV step and releasing inactiva-
tion by a series of hyperpolarizing steps from -100 to -70 mV (Fig 6A). Fast and slow time con-
stants (Taufast and Tauslow) were found by fitting bi-exponential equations to the decaying
currents and were similar for equine and human KV11.1 (Fig 6B). For both equine and human
KV11.1, Taufast predominated over Tauslow at more hyperpolarized voltages (Fig 6C).
KV11.1 and KCNE2 have been proposed to interact in cardiac cells [12]. Co-expression
of equine KV11.1 and KCNE2 resulted in a reduction of the average steady-state current by
42.3±6.4% (Fig 7A and 7B). The gating properties were similar to those of homomeric KV11.1
channels (Fig 7A) and there were no effects on current deactivation (Fig 7C and 7D).
Pharmaceutical block of KV11.1 can cause arrhythmias and sudden cardiac death [26]. Aro-
matic residues in the S6 transmembrane segment, Y-652 and F-656 are critical for the interac-
tion with pharmaceutical compounds [27,28]. These residues are also present in equine
KV11.1. Pharmacological block of the equine KV11.1 channel was tested with the histamine H1
receptor antagonist terfenadine. A concentration-dependent block of KV11.1 by terfenadine
(0.01, 0.03, 0.1, 0.3, 1, 3 and 10 μM) was found (Fig 8). The IC50 was 0.42±0.14 μM for steady
state currents and 0.37±0.06 μM for tail currents, n = 4.
To determine the physiological importance of KV11.1 currents in equine hearts, the effect of
terfenadine (10 μM) was tested in arterially perfused sections of the right ventricle (RV), the
wedge model. Action potentials were recorded from the midmyocardial region at different pac-
ing rates (4000, 2000, 1000, 500, 333 and 250 ms BCL) using floating microelectrodes (Fig 9).
In the presence of terfenadine, the action potential duration at 90% repolarization (APD90)
was significantly increased at BCLs of 1000 and 2000 ms (Fig 9B). At 250 ms BCL we could not
get capture in (5/6) wedges in controls, in the presence of terfenadine the prolonged action
potential and concomitant increased refractory period prevented initiation of action potential
at 250 ms BCL in 6/6 wedges.
Discussion
In this study we successfully cloned full equine KV11.1 and partial KCNE2 cDNA. Currents
were characterized by TEVC. The electrophysiological gating properties of the equine KV11.1
channel and KV11.1/KCNE2 channel complex were found to resemble those of the human
KV11.1 and KV11.1/KCNE2 channels. The currents showed a bell-shaped steady-state current-
voltage relationship that peaked at 0 mv due to a prominent inactivation. Furthermore, hyper-
polarization resulted in a rapid recovery followed by slow channel deactivation. These
electrophysiological properties are hallmarks of the KV11.1 channel and KV11.1/KCNE2 chan-
nel complex [12,29]. However, equine currents were larger compared to human KV11.1 and
the voltage dependence of activation was shifted to more negative values. The onset of inactiva-
tion was slower in equine KV11.1 compared to human KV11.1, and we are speculating whether
these differences in kinetics can contribute to the increase in KV11.1 current. There were no
differences in the rectification of the K+ current, the voltage-dependence of inactivation,
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reversal potential or deactivation kinetics between equine and human KV11.1. Co-expression
of KCNE2 resulted in a reduction of currents for both equine and human KV11.1. In accor-
dance with Y-652 and F-656 being present in equine KV11.1, currents were blocked by terfena-
dine in the same concentration range as the human KV11.1 currents [28]. Finally we
demonstrated that KV11.1 plays a functional role in cardiac repolarization in equine right ven-
tricle, as application of terfenadine resulted in a prolongation of APD90 which was most promi-
nent at slower pacing rates.
Fig 7. The effect of equine KCNE2 on equine KV11.1. Equine KV11.1 and KV11.1/KCNE2 expressed in Xenopus laevis oocytes. (A) Representative
recordings. (B) Steady-state currents as a function of voltage, n = 10. C) Time constants (τfast and τslow) of deactivation of equine KV11.1 (n = 8) and KV11.1/
KCNE2 (n = 10) plotted as a function of voltage. D) The relative weight of the fast time constant (Taufast).
doi:10.1371/journal.pone.0138320.g007
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Sequence and electrophysiological properties
The equine KV11.1 polypeptide sequence was highly similar to the human equivalent (99%
similarity). This homology is greater than for any other previously sequenced animal KV11.1
polypeptide. Importantly, the signature sequence which shapes the selectivity filter of the chan-
nel was conserved. This part is essential to maintain the selectivity towards K+ and thereby the
Fig 8. Equine KV11.1 channels are blocked by terfenadine. Equine (n = 4) KV11.1 expressed in Xenopus
laevis oocytes. Currents were activated by a repeated depolarization to 0 mV from a holding of -80 mV. (A)
Representative recordings in control and in the presence of 0.01, 0.03, 0.1, 0.3, 1, 3 and 10 μM terfenadine.
Currents got successively smaller as concentrations were increased. (B) Dose-response for the effect of
terfenadine on the equine KV11.1 steady-state currents at the end of a depolarizing step to 0 mV. (C) Dose-
response for the effect of terfenadine on the equine KV11.1 peak tail current after repolarization from 0 mV to
-80 mV. KV11.1 currents are expressed as a fractional value (Idrug/Icontrol). On the X-axis values non-
transformed values are shown. A non-linear regression was fitted to the data.
doi:10.1371/journal.pone.0138320.g008
Fig 9. Physiological importance of KV11.1 in equine right ventricle. Action potentials were recorded from
the midmyocardium in right ventricular wedges in absence or presence of terfenadine (10 μM). (A)
Representative recordings at 2000 ms BCL. (B) Action potential duration at 90% repolarization (APD90) in
absence or presence of terfenadine as a function of basic cycle length, n = 6.
doi:10.1371/journal.pone.0138320.g009
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appropriate function of the channel [30] and in line with this, we found similar reversal poten-
tials for equine and human KV11.1. Likewise, 100% conservation was seen for the transmem-
brane segments S1-S3, the S4 segment, which is essential for voltage sensing, and the pore
forming S5 and S6 segments, which are hallmarks of voltage dependent K+ channels [31]. In
the PAS domain, a p.A97S substitution was found in the equine KV11.1 polypeptide encoded
by both the genomic sequence from the EquCab2.0 project [19] and the cDNA sequence
obtained here.This substitution has not been reported in other species. Functionally the PAS
domain is of importance for the deactivation kinetics [32], likely by interaction between resi-
dues 26–135 in the PAS-domain and residues 749–872 in the CNBD [33]. However, no differ-
ences in deactivation kinetics were found between equine and human KV11.1. A serine to
alanine substitution is regarded as conserved suggesting that this substitution may be of little
significance. To the authors’ knowledge, this mutation has not been published as a cause for
altered properties of the KV11.1 channel. The CNBD domain was found to be 100% identical.
Another important region of the KV11.1 channel is the amphipathic alpha helix at residues 13–
23, which is involved in protein-protein and protein-membrane interactions [33]. This region
was also found to be 100% identical in equine and human KV11.1isoforms. The majority of the
17 amino acid changes in the equine versus the human sequence map to the proximal domain
between the PAS and the first transmembrane segment (S1). This region has been reported to
be important for activation kinetics [34,35]. We found a left shift in the voltage dependence of
current activation, however, the time constants of activation were similar for equine and
human KV11.1. One interesting finding was the presence of a p.E444D substitution positioned
in the extracellular loop between S1 and S2 in the equine KV11.1. This substitution is present in
the peptide sequence of most species, except in humans and rabbits. p.E444D has previously
been associated with long QT syndrome in a Chinese family [25], however, the electrophysio-
logical properties of the substitution has not been tested in vitro [25] and the importance of the
substitution remains speculative.
Regulation of KV11.1 by KCNE2
The equine KCNE2 protein sequence was quite similar to the human equivalent (90% homol-
ogy). The transmembrane regions were identical and the N6 and N29 glycosylation sites, as
well as the T71 and S74 phosphorylation sites were conserved [36]. Co-expression with
KCNE2 caused an approximately 40% reduction in steady-state equine KV11.1 currents, in
agreement the effects of KCNE2 on human KV11.1 amplitude [12,37]. The reports describing
the effects of KCNE2 on KV11.1 kinetics are not consistent (Reviewed in [36]). The role of
KCNE2 in IKr has been questioned as co-expression of KV11.1 and KCNE2 does not recapitu-
late native IKr [38] and recently it has been proposed that KCNE2 is modulating KV11.1 by
accelerating degradation of the KV11.1 protein [37]. It is, however, possible that interactions
with other regulatory subunits affect the conductance and gating of the equine KV11.1 channel
[32,39,40]. In humans, an association of the KV11.1 channel with the auxiliary β subunit
KCNE1 has been proposed to regulate the K+ conduction of the channel [41] and in horses one
study has described a possible interaction between KV11.1 and KCNE1 but no electrophysio-
logical measurements have been performed on this equine channel complex [42]. Another rea-
son for the discrepancy between native IKr and expressed KV11.1 could be the presence of
different splice variants in native tissue. In humans, splice variants encoding a KV11.1 channel
with a truncated N terminal (hERG1b) [43] and a c-terminal splice variant ERGUSO [40][44]
has been reported. The ERG1b or the ERGUSO variants were not detected in horse hearts [42]
but other splice variants could be speculated to be present.
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Pharmacology
The aromatic residues Y-652 and F-656 located in the central cavity of the KV11.1 channel
have been demonstrated to be critical sites of interaction with structurally diverse drugs. Muta-
tions of these residues have been shown to drastically decrease susceptibility of the KV11.1
channel to pharmacological block by various compounds [26,27].These residues were con-
served in the equine KV11.1 sequence. To test if equine KV11.1 is equally sensitive to pharma-
cological blockade as the human isoform, we tested the effect of the histamine H1 receptor
antagonist terfenadine. Terfenadine has been shown to block the human KV11.1 channel at
concentrations relevant to its therapeutic levels [45], and it was removed from the market after
frequent reports of syncope, QT prolongation and torsade de pointes in humans. The equine
KV11.1 channel exhibited a dose-dependent block by terfenadine with an IC50 value of
0.42 μM, which is comparable to 0.36 μM described for the human KV11.1 channel [28].
Physiological Importance of Equine KV11.1
The physiological importance of KV11.1 in equine hearts was determined by addition of terfena-
dine (10 μM) to arterially perfused wedges from the right ventricle. Terfenadine application
resulted in a prolongation of the APD90 most prominently at slower pacing rates. At 2000 ms
BCL, the APD90 was increased by 17% indicating that IKr plays an important role in action poten-
tial repolarization in equine right ventricle. These results are in agreement with Finley et al. that
found a similar prolongation of APD90 after application of the IKr blocker cisapride to epicardial
slice preparations of equine hearts [42]. Taken together, this suggests that LQTS, both in the con-
genital and acquired form could be of relevance in equine patients as in humans. In humans it
has been proposed that a “repolarization reserve” exists [46]. Many different currents contribute
to repolarization and as a consequence loss of one component (such as IKr) normally does not
result in repolarization failure, but if several components of the repolarization reserve are
reduced, this may result in failure of repolarization [46]. It will thus be of great importance to
determine other currents that are contributing to repolarization in equine cardiomyocytes.
Conclusions
This study has shown that the equine Kv11.1 and KCNE2 cDNA sequences are highly similar to
the human and that they encode a functional KV11.1 and KV11.1/KCNE2 channel complex in
Xenopus laevis oocytes. Equine currents were larger compared to human KV11.1 and the voltage
dependence of activation was shifted to more negative values (V1/2 = -14.2±1.1 mV and -17.3
±0.7, respectively). The onset of inactivation was slower in equine KV11.1 compared to human
KV11.1. Furthermore, the equine channel is susceptible to the H1 receptor antagonist terfenadine
in the same dose range as the human KV11.1 channel. Finally, application of terfenadine to a
right ventricular wedge resulted in a prolongation of APD90, indicating that the KV11.1 channel
plays a pivotal role in repolarization of the equine heart, as it does in the human heart.
The findings in this study suggest that horses could be disposed to both congenital LQT2,
LQT6 and acquired LQTS. This is of importance to veterinary pathologists examining cases of
sudden death in horses and to veterinary practitioners treating horses with drugs known to
block the KV11.1 channel.
Limitations
The experiments were performed at room temperature using Xenopus laevis oocytes. In Xeno-
pus laevis oocytes, as in all heterologous expression systems, endogenous factors may affect the
currents.
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